Zylox-Tonbridge Medical Expertise Full Yr 2022 Earnings: EPS Beats Expectations
Zylox-Tonbridge Medical Expertise (HKG:2190) Full Yr 2022 Outcomes
Key Monetary Outcomes
- Income: CN¥334.1m (up 88% from FY 2021).
- Web loss: CN¥113.6m (loss narrowed by 43% from FY 2021).
- CN¥0.34 loss per share (improved from CN¥0.68 loss in FY 2021).
All figures proven within the chart above are for the trailing 12 month (TTM) interval
Zylox-Tonbridge Medical Expertise EPS Beats Expectations
Income was in keeping with analyst estimates. Earnings per share (EPS) surpassed analyst estimates by 2.9%.
Trying forward, income is forecast to develop 27% p.a. on common in the course of the subsequent 3 years, in comparison with a 27% progress forecast for the Medical Tools business in Hong Kong.
Efficiency of the Hong Kong Medical Tools business.
The corporate’s shares are down 2.6% from per week in the past.
Stability Sheet Evaluation
Simply as traders should take into account earnings, it is usually vital to take into consideration the power of an organization’s stability sheet. We now have a graphic illustration of Zylox-Tonbridge Medical Expertise’s stability sheet and an in-depth evaluation of the corporate’s monetary place.
Valuation is advanced, however we’re serving to make it easy.
Discover out whether or not Zylox-Tonbridge Medical Expertise is doubtlessly over or undervalued by testing our complete evaluation, which incorporates honest worth estimates, dangers and warnings, dividends, insider transactions and monetary well being.
View the Free Evaluation
Have suggestions on this text? Involved concerning the content material? Get in contact with us instantly. Alternatively, e mail editorial-team (at) simplywallst.com.
This text by Merely Wall St is basic in nature. We offer commentary based mostly on historic information and analyst forecasts solely utilizing an unbiased methodology and our articles usually are not supposed to be monetary recommendation. It doesn’t represent a suggestion to purchase or promote any inventory, and doesn’t take account of your goals, or your monetary state of affairs. We goal to carry you long-term centered evaluation pushed by basic information. Word that our evaluation could not issue within the newest price-sensitive firm bulletins or qualitative materials. Merely Wall St has no place in any shares talked about.
